Recombinant Proteins and Enzymes

Biogenomics’ core competency is the production of Recombinant Proteins. One of the most important advantages of using r-DNA derived proteins or enzymes is that products are Animal-Origin-Free (AOF), thus eliminating the risk of viral and other adventitious agents. Biogenomics has developed a portfolio of Cell-Culture Reagents and Enzymes. These reagents are ideal replacements for animal-derived proteins and enzymes so that the entire production process can be made completely animal origin free.

RECOMBINANT PROTEINS AND ENZYMES (AOF) (MARKETED PRODUCTS)

Recombinant Insulin (For Cell culture)
Recombinant Trypsin (Mammalian cell culture for Insulin production and proteomics applications)
Recombinant Carboxy peptidase (For Insulin manufacturing)
Recombinant Enterokinase
Recombinant Transferrin.

Request for the product brochure.

RECOMBINANT PROTEINS AND ENZYMES (AOF) DEVELOPMENT STAGE

Recombinant Insulin like Growth factor-1
Recombinant Protein A
Recombinant Human Serum Albumin

Vision & Mission

Biogenomics is a Science driven enterprise. Led by eminent scientists, business professionals and a focussed team of molecular biologists, microbiologists and protein engineers, Biogenomics has, in a short span of 10 years, developed dozens of Biopharmaceuticals and Biotech products.

Biogenomics has a thorough understanding of both microbial and mammalian technologies and an ability to develop own clones and cell lines. The resulting unique platform technology has allowed Biogenomics to rapidly deliver efficient, cost-effective, scalable and internationally acceptable technologies and products.

With fully integrated ‘Bench to Manufacturing’ facilities, Biogenomics ensures a quick turnaround, adaptive technology and is capable of full-scale manufacturing.

Biogenomics is consistently able to meet and exceed all regulatory standards in its products, processes and facilities.

Our proven capability to research, develop, customize and manufacture high-value biopharmaceuticals is an endorsement of our ability to meet global benchmarks. Our strengths lie in our scientific forte, proprietary technologies and state-of-the-art facilities.

Team

The Company is run by dynamic Board of Directors headed by Mr. R M Parakh, Chairman and Managing Director. Mr. Parakh is a well known and highly respected prominent NRI settled in Oman over the last 32 years. He is also the Managing Director - Finance of Saud Bahwan Group, one of largest trading house in the Gulf having annual turnover of US$ 4.5 Billion.

Biogenomics has a thorough understanding of both microbial and mammalian technologies and an ability to develop own clones and cell lines. The resulting unique platform technology has allowed Biogenomics to rapidly deliver efficient, cost-effective, scalable and internationally acceptable technologies and products.

With fully integrated ‘Bench to Manufacturing’ facilities, Biogenomics ensures a quick turnaround, adaptive technology and is capable of full-scale manufacturing.

Biogenomics is consistently able to meet and exceed all regulatory standards in its products, processes and facilities.

Our proven capability to research, develop, customize and manufacture high-value biopharmaceuticals is an endorsement of our ability to meet global benchmarks. Our strengths lie in our scientific forte, proprietary technologies and state-of-the-art facilities.

Strength

The Company is run by dynamic Board of Directors headed by Mr. R M Parakh, Chairman and Managing Director. Mr. Parakh is a well known and highly respected prominent NRI settled in Oman over the last 32 years. He is also the Managing Director - Finance of Saud Bahwan Group, one of largest trading house in the Gulf having annual turnover of US$ 4.5 Billion.

Biogenomics has a thorough understanding of both microbial and mammalian technologies and an ability to develop own clones and cell lines. The resulting unique platform technology has allowed Biogenomics to rapidly deliver efficient, cost-effective, scalable and internationally acceptable technologies and products.

With fully integrated ‘Bench to Manufacturing’ facilities, Biogenomics ensures a quick turnaround, adaptive technology and is capable of full-scale manufacturing.

Biogenomics is consistently able to meet and exceed all regulatory standards in its products, processes and facilities.

Our proven capability to research, develop, customize and manufacture high-value biopharmaceuticals is an endorsement of our ability to meet global benchmarks. Our strengths lie in our scientific forte, proprietary technologies and state-of-the-art facilities.